Here's a Bull Spread Strategy on Aurobindo Pharma by HDFC Securities

The stock price has broken out from the downward slopping trendline

markets, stock market, sensex, correction, nifty, shares, growth, profit, economy, gain
Long build up was seen in Aurobindo Pharma futures where we have seen a 16 per cent rise in the Open Interest with price rising by 3%.
Nandish Shah Mumbai
1 min read Last Updated : Dec 28 2020 | 8:55 AM IST
Bull Spread Strategy on Aurobindo Pharma

Buy Aurobindo Pharma Dec 900 Call at Rs 30 and simultaneously sell Dec 960 Call at Rs 10

Lot Size: 650

Cost of the strategy: Rs 20 (Rs 13,000 per strategy)

Maximum profit: Rs 26,000 if Aurobindo Pharma closes at or above 960 till 31 Dec expiry

Breakeven Point: Rs 920

Also Read


Rationale:

-- Long build up was seen in Aurobindo Pharma futures where we have seen a 16 per cent rise in the Open Interest with price rising by 3%

-- Stock Price has broken out from the downward slopping trendline, adjoining the highs of December 7 and December 21 on the daily chart with higher volumes

-- RSI Oscillator is showing strength in the stock; DI is trading above minus DI while ADX is placed above 25, indicating momentum in the current uptrend

-- Pharma as a sector is showing strength on the chart

==================
Disclaimer: Nandish Shah is Technical Research Analyst at HDFC Securities. He doesn't hold any position in the stock. Views are personal.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :MarketsMarket technicalsAurobindo Pharma

Next Story